An interventional study of Boric acid and Povidone iodine 10% in Otomycosis, sponsored by Mansoura University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by Mansoura University · Not applicable, Interventional, and Treatment
This study compares two topical agents for the treatment of fungal infection of the external auditory canal: boric acid and a 10% povidone-iodine solution
Mansoura University is the lead sponsor of 1,119 studies on the registry; 183 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Boric acid
Drug: Povidone iodine 10%
Boric acid is topically applied to the external auditory canal for treatment of otomycosis
10% povidone iodine solution is topically applied to the external auditory canal for the treatment of otomycosis
objective clinical response
clinical response is assessed by ear examination by presence or absence of fungal hyphae inside the external auditory canal
Time frame: Days 7, 14, and 28 after treatment
Microbiological response
Microbiological response is evaluated by obtaining cultures from the external auditory canal searching for fungal growth
Time frame: day 28 after treatment
subjective pain response
pain is evaluated on a visual analogue scale from 0 to 10
Time frame: days 7, 14, and 28 after treatment
subjective itching response
itching is evaluated on a visual analogue scale from 0 to 10
Time frame: days 7, 14, and 28 after treatment
Plan to share: No
Ran from Dec 2024 to primary completion in Dec 2025, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Boric acid · Povidone-Iodine
Otomycosis